Table 1. Clinical characteristics of the cohort and two subtype clusters.
| Variables | The cohort (n=160) | Cluster 1 (n=82) | Cluster 2 (n=78) |
|---|---|---|---|
| Age (mean ± SD) | 62±12 | 58±11 | 67±11 |
| Gender (n, %) | |||
| Male | 137 (85.6) | 71 (86.6) | 66 (84.6) |
| Female | 23 (14.4) | 11 (13.4) | 12 (15.4) |
| Race (n, %) | |||
| White | 99 (61.9) | 40 (48.8) | 59 (75.6) |
| Asian | 38 (23.8) | 35 (42.7) | 3 (3.8) |
| Black or African American | 5 (3.1) | 5 (6.1) | 0 (0) |
| Unknown | 18 (11.3) | 2 (2.4) | 16 (20.5) |
| Grade (n, %) | |||
| G1 | 16 (10.0) | 15 (18.3) | 1 (1.3) |
| G2 | 66 (41.3) | 40 (48.8) | 26 (33.3) |
| G3 | 43 (26.9) | 17 (20.7) | 26 (33.3) |
| Unknown | 35 (21.9) | 10 (12.2) | 25 (32.1) |
| AJCC T (n, %) | |||
| T0–T2 | 65 (40.6) | 35 (42.7) | 30 (38.5) |
| T3–T4 | 80 (50.0) | 43 (52.5) | 37 (47.5) |
| Unknown | 15 (9.4) | 4 (4.9) | 11 (14.1) |
| AJCC N (n, %) | |||
| N0 | 65 (40.6) | 44 (53.7) | 21 (26.9) |
| N1–N3 | 78 (48.8) | 33 (40.2) | 45 (57.6) |
| Unknown | 17 (10.7) | 5 (6.1) | 12 (15.4) |
| AJCC M (n, %) | |||
| M0 | 121 (75.6) | 70 (85.4) | 51 (65.4) |
| M1 | 8 (5.0) | 2 (2.4) | 6 (7.7) |
| Unknown | 31 (19.3) | 10 (12.2) | 21 (26.9) |
| Pathological stage (n, %) | |||
| Stage I | 16 (10.0) | 7 (8.5) | 9 (11.5) |
| Stage II | 68 (42.5) | 45 (54.9) | 23 (29.5) |
| Stage III | 49 (30.6) | 23 (28.0) | 26 (33.3) |
| Stage IV | 8 (5.0) | 2 (2.4) | 6 (7.7) |
| Unknown | 19 (11.9) | 5 (6.1) | 14 (17.9) |
| Status (n, %) | |||
| Alive | 97 (60.6) | 56 (68.3) | 41 (52.6) |
| Death | 63 (39.4) | 26 (31.7) | 37 (47.4) |
| Follow-up (m) (mean ± SD) | 18.1±14.5 | 17.6±13.1 | 18.6±16.0 |
AJCC, American Joint Committee on Cancer.